Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$1.94M$1.94M−82.4% vs Q1 2022 Net Income-$13.18M-$13.18MN/M vs Q1 2022 EPS, diluted—
Operating Income-$15,511,000N/M Operating Cash Flow-$10,996,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived-$11,044,000N/M Margins · derivedOperating margin-801.2%−733.3 pt vs Q1 2022
Net margin-680.9%−634.5 pt vs Q1 2022
ended Mar 31, 2023 · filed May 11, 2023 · 41 d after period end